Logo image of BTLS.BR

BIOTALYS NV (BTLS.BR) Stock Fundamental Analysis

EBR:BTLS - BE0974386188 - Common Stock

4.1 EUR
-0.15 (-3.53%)
Last: 9/5/2025, 7:00:00 PM
Fundamental Rating

2

Overall BTLS gets a fundamental rating of 2 out of 10. We evaluated BTLS against 68 industry peers in the Chemicals industry. The financial health of BTLS is average, but there are quite some concerns on its profitability. BTLS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BTLS has reported negative net income.
BTLS had a negative operating cash flow in the past year.
BTLS had negative earnings in each of the past 5 years.
In the past 5 years BTLS always reported negative operating cash flow.
BTLS.BR Yearly Net Income VS EBIT VS OCF VS FCFBTLS.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

BTLS has a worse Return On Assets (-35.89%) than 89.71% of its industry peers.
Looking at the Return On Equity, with a value of -47.77%, BTLS is doing worse than 86.76% of the companies in the same industry.
Industry RankSector Rank
ROA -35.89%
ROE -47.77%
ROIC N/A
ROA(3y)-45.95%
ROA(5y)-38.32%
ROE(3y)-62.54%
ROE(5y)-51.65%
ROIC(3y)N/A
ROIC(5y)N/A
BTLS.BR Yearly ROA, ROE, ROICBTLS.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BTLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTLS.BR Yearly Profit, Operating, Gross MarginsBTLS.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

BTLS has more shares outstanding than it did 1 year ago.
BTLS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BTLS has been reduced compared to a year ago.
BTLS.BR Yearly Shares OutstandingBTLS.BR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
BTLS.BR Yearly Total Debt VS Total AssetsBTLS.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 9.68 indicates that BTLS is not in any danger for bankruptcy at the moment.
BTLS's Altman-Z score of 9.68 is amongst the best of the industry. BTLS outperforms 100.00% of its industry peers.
BTLS has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
BTLS's Debt to Equity ratio of 0.13 is fine compared to the rest of the industry. BTLS outperforms 79.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z 9.68
ROIC/WACCN/A
WACCN/A
BTLS.BR Yearly LT Debt VS Equity VS FCFBTLS.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 5.50 indicates that BTLS has no problem at all paying its short term obligations.
BTLS has a Current ratio of 5.50. This is amongst the best in the industry. BTLS outperforms 97.06% of its industry peers.
BTLS has a Quick Ratio of 5.50. This indicates that BTLS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.50, BTLS belongs to the top of the industry, outperforming 98.53% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.5
Quick Ratio 5.5
BTLS.BR Yearly Current Assets VS Current LiabilitesBTLS.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 38.92% over the past year.
EPS 1Y (TTM)38.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BTLS will show a decrease in Earnings Per Share. The EPS will decrease by -2.57% on average per year.
The Revenue is expected to grow by 10.43% on average over the next years. This is quite good.
EPS Next Y-3.51%
EPS Next 2Y12.78%
EPS Next 3Y-2.57%
EPS Next 5YN/A
Revenue Next Year-52%
Revenue Next 2Y3.92%
Revenue Next 3Y10.43%
Revenue Next 5YN/A

3.3 Evolution

BTLS.BR Yearly Revenue VS EstimatesBTLS.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2023 2024 2025 2026 2027 2M 4M 6M
BTLS.BR Yearly EPS VS EstimatesBTLS.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.1 -0.2 -0.3 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BTLS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BTLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTLS.BR Price Earnings VS Forward Price EarningsBTLS.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTLS.BR Per share dataBTLS.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

A cheap valuation may be justified as BTLS's earnings are expected to decrease with -2.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.78%
EPS Next 3Y-2.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BTLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOTALYS NV

EBR:BTLS (9/5/2025, 7:00:00 PM)

4.1

-0.15 (-3.53%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners23.43%
Inst Owner ChangeN/A
Ins Owners4.85%
Ins Owner ChangeN/A
Market Cap153.83M
Analysts86.67
Price Target7.58 (84.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)15.25%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)51.14%
EPS NY rev (3m)51.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)20%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.57
P/tB 5.69
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0
BVpS0.74
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.89%
ROE -47.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.95%
ROA(5y)-38.32%
ROE(3y)-62.54%
ROE(5y)-51.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.55%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.5
Quick Ratio 5.5
Altman-Z 9.68
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)25.97%
Cap/Depr(5y)109.26%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.42%
EPS Next Y-3.51%
EPS Next 2Y12.78%
EPS Next 3Y-2.57%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-52%
Revenue Next 2Y3.92%
Revenue Next 3Y10.43%
Revenue Next 5YN/A
EBIT growth 1Y35.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.54%
EBIT Next 3Y-39.01%
EBIT Next 5YN/A
FCF growth 1Y31.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.8%
OCF growth 3YN/A
OCF growth 5YN/A